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Figure 1. Bioluminescence images of tumours in the brain of nude 
mice at different time after cell injection.
Figure 2. Magnetic Resonance Imaging of the same animal as 
depicted in Figure1 (white arrow indicate tumour area) at the 
indicated times. In the figure contrast enhanced T1-weighted images 
were acquired using Gadolinium-DTPA (Magnevist®) injected i.v. 
through the tail vein at 100-300 mmol/kg.
Figure 3. Correlation between bioluminescence and MRI in all 
animals examined
Introduction
Glioblastoma represents the most 
malignant and lethal among brain tumours 
because of its highly infiltration capacity 
and invasion into the normal brain that 
account for its resistance to treatments 
(chemotherapy and radiotherapy). Recent 
advance and development of technologies 
to non-invasively image brain tumour 
growth in living animals can open an 
opportunity to monitor directly the efficacy 
of the treatment on tumour development. 
In vivo bioluminescence imaging is based 
on light-emitting enzymes, luciferases, 
which require specific substrates for light 
production. When linked to a specific 
biological process/pathway in an animal 
model of human disease, the enzyme-
substrate interactions become biological 
indicators that can be studied. 
In order to explore and compare different 
imaging modalities (MRI and 
bioluminescence imaging) we have 
validated the use of bioluminescence 
imaging to monitor glioblastoma 
progression in vivo. 
The human glioma cell line (DBTRG-05MG) 
derived from an adult patient with 
glioblastoma multiforme who had been 
treated with local brain irradiation and 
multidrug chemotherapy has been used for 
the experiment. The DBTRG-05MG cell line 
was stably transfected with TCF-luciferase
and orthotopic implantated onto 
immunodeficient mice. Bioluminescence 
technology was used to follow tumour 
growth in parallel with classical MRI on the 
same animals. 
Results 
After injection of glioma cells stably transfected with luciferase
we followed the development of the tumours using 
bioluminescence and MRI in parallel for a total of 6 weeks. 
Using bioluminescence, 1 week after cell engraftment, glioma
cells were visible in almost all animals (Figure 1). MRI detected 
tumour development only starting from 2-3 weeks after cell 
injection (Figure 2). However, when the two techniques were 
compared over time we obtained a nice correlation (Figure 3). 3-
D reconstruction of luminescence signal shoe distribution of light 
emitted by tumour cells in the mouse brain (Figure 4). 6 week 
after injection, animals were sacrificed. 
Conclusions
Data presented here suggested that:
Bioluminescence can be used to monitor in vivo 
intracranial tumor growth
The potentiality of bioluminescence and MRI imaging may 
open new perspectives also to use these tools for drug 
discovery by directly monitoring the efficacy of the therapy
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Figure 4. 3D-reconstruction of luminescent tumor in 
the mouse brain 5 weeks after the injection
r2=0.79
Material and Methods
Cell and surgery details: DBTRG cells were stably 
transfected With TCF-Luciferase and cultured at limiting 
clonal dilution. One Clone with high luciferase expression 
was chosen for the in vivo experiments. 5x10^5 cells in 5 µl 
of PBS 1X were injected in Each animal under sterotactic
guidance (coordinates from bregma: + 0.5mm anterior, + 
2.2mm
lateral and - 3.0mm depth). 
Optical Imaging: A VivoVision Systems, IVIS® 200 Series, 
(Xenogen Corporation, Alameda USA) was used for all 
experiments. Images were acquired and analyzed with 
Living Image 2.6 e and Living Image 3D (Xenogen
Corporation, Alameda USA). Acquisition details: FOV= 
4x4cm centred on The brain; (f/stop) = 1. Binnig factor, 
exposition time and use Of filters of emission set for 3D 
reconstruction was set. After
a pre acquisition it was performed a post D-Luciferin (firefly, 
Potassium salt, Xenogen), 150mg/kg/10ml IP, injection 
acquisition. Optical imaging acquisitions will be carried out
after 1-2-3-4-5 weeks from cell inoculation.
Magnetic Resonance Imaging Images were acquired at 4.7 
T using a helmet shaped coil optimized for the mouse brain. 
After a scout acquisition to localize the brain, multislice T2 
Weighted RARE images were acquired to measure the 
tumor volume. Acquisition parameters were: TR=5000 ms 
TE=60 Ms FOV=2.5x2.5 cm2; slice thickness=1mm, number 
of slice = 11. MRI examinations were performed 2, 4, 6 
weeks after cell implantation. At selected time points 
contrast enhanced T1 weighted images were acquired using 
Gadolinium-DTPA (Magnevist®) injected i.v. trough the tail 
vein at
100-300 mmol/kg.
